Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:36 PM ET 8-K
Leadership Change Target Corp TGT

Target Leadership Change

Target Corporation has elected Sally Grimes to its Board of Directors, effective December 1, 2026. Ms. Grimes, the former CEO of Diageo North America and Clif Bar & Company, will serve on the Audit & Risk and Infrastructure & Finance committees. Her appointment is intended to bring extensive consumer brand and innovation expertise to Target's long-term growth strategy.

4:36 PM ET 8-K
Leadership Change Xerox Holdings Corp XRX

Xerox Holdings Leadership Change

William Twomey, Vice President and Chief Accounting Officer, has resigned from Xerox Holdings Corporation effective November 30, 2026, to pursue other opportunities. Chuck Butler, the company's current CFO, will serve as the interim principal accounting officer while a search for a permanent replacement is conducted.

4:36 PM ET 10-Q
Financial Results Pono Capital Four, Inc. PONO

Pono Capital Four Q3 2026 Results: Net Income $507K

Pono Capital Four, Inc. reported a net income of $1,571,816 for the period from inception (January 2, 2026) through September 30, 2026, primarily driven by $2,346,853 in income earned on marketable securities held in the Trust Account. As a shell company, it maintains $122,346,853 in its Trust Account while reporting a shareholders' deficit of $2,654,584 due to the redemption value of Class A ordinary shares.

Key figure
Net income $507K
4:36 PM ET 8-K
Financial Results Gemini Space Station, Inc. GEMI

Gemini Space Station Financial Results

Gemini Space Station reported Q3 2026 total revenue of $40.9 million, a 19% year-over-year decline driven by a 73% drop in platform spot trading volume. Despite the revenue decline, the company improved its net loss by 63% year-over-year to $58.6 million through a 30% reduction in operating expenses and lower headcount.

Term
Q3 2026

“Operating expenses declined for a third consecutive quarter, and as we invest in growth, we intend to stay disciplined about where those dollars go. We’re clear-eyed about the work ahead and committed to getting it right: deepening our relationships with the customers who use Gemini, continuing to iterate, and investing where customers and markets are headed. We expect to be judged on results, and we intend to earn the confidence of our customers and shareholders one quarter at a time.”

Tyler Winklevoss, CEO of Gemini

“We started Gemini in 2014 because we believed crypto would change how people save, spend and move value, and we’re in this for the long term. Gemini 2.0 is our bet that the platforms that last will be the ones that own the regulated infrastructure underneath. We’re building ours to serve customers directly and to be something other platforms can build on.”

Cameron Winklevoss, President of Gemini
4:36 PM ET 8-K
Licensing Deal Tempest Therapeutics, Inc. TPST

Tempest Therapeutics Licensing Deal with Hebei Senlang Biotechnology Co., Ltd.

Tempest Therapeutics has exercised its option to obtain an exclusive license for Senlang’s CD7-targeted lentiviral in vivo CAR-T platform and associated candidates worldwide, excluding China. The deal includes the lead BCMA/GPRC5D dual-targeting candidate (TPST-4903) currently in a Phase 1 study for relapsed or refractory multiple myeloma. This exercise follows encouraging preliminary clinical data from 13 patients and expands Tempest's delivery capabilities alongside its existing LNP platform.

Counterparty
Hebei Senlang Biotechnology Co., Ltd.

“Our decision to exercise this option and obtain an exclusive license reflects our confidence in the platform and the differentiating clinical observations from the lead program.”

Matt Angel, Ph.D., President and Chief Executive Officer of Tempest

“With the addition of this clinical-stage lentiviral platform alongside our targeted LNP platform, we have expanded our capabilities to develop in vivo immune reset therapies for cancer and autoimmune disease.”

Matt Angel, Ph.D., President and Chief Executive Officer of Tempest
4:36 PM ET Form 4
Insider Selling Core Scientific, Inc. CORZ

Core Scientific Insider Todd M. Duchene Sells $125K of Stock

Todd M. Duchene sold 10,000 shares of Core Scientific, Inc. at $12.39 to $12.70 a share (average $12.45) in 2 transactions, worth $125K in total on Nov 9, 2026. Shares held after the trade: 1,113,286 (-0.2%).

Value
$125K
Shares
10,000
Average price
$12.45
Holding change
-0.2%
Trade date
Nov 9, 2026
4:36 PM ET 10-Q
Financial Results enCore Energy Corp. EU

enCore Energy Q3 2026 Results: Net Loss of $33.9M, Loss Widens

enCore Energy Corp. is a non-accelerated filer and smaller reporting company focused on uranium exploration and extraction. As of November 9, 2026, the company had 195,668,102 common shares outstanding and reported a history of negative operating cash flows while pursuing an expansion-by-acquisition strategy.

Key figure
Net loss $33.9M
4:36 PM ET Form 4
Insider Selling Datadog, Inc. DDOG

Datadog CTO Alexis Le-Quoc Sells $8.97M of Stock

Alexis Le-Quoc, CTO, sold 49,961 shares of Datadog, Inc. at $178.01 to $181.68 a share (average $179.52) in 5 transactions, worth $8.97M in total on Nov 9, 2026. Shares held after the trade: 438,072 (-0.0%).

Value
$8.97M
Shares
49,961
Average price
$179.52
Role
CTO
Holding change
-0.0%
Trade date
Nov 9, 2026
4:36 PM ET 10-Q
Financial Results Cibus, Inc. CBUS

Cibus Q3 2026 Results: Net Loss of $21.9M, Loss Narrows

Cibus, Inc. reported a net loss of $21.9 million for the third quarter of 2026, with revenue increasing to $0.8 million from $0.6 million in the prior year period. The company's cash position improved slightly to $10.7 million as of September 30, 2026, supported by $31.0 million in net cash provided by financing activities during the first nine months of the year.

Key figure
Net loss $21.9M
4:36 PM ET 8-K
Loan & Debt Nakamoto Inc. NAKA

Nakamoto $165M Debt Financing with Kraken

Nakamoto Inc. entered into a second amendment to its Master Loan Agreement with Kraken to extend the maturity of 60 million USDT of its 165 million USDT outstanding principal from December 2026 to December 2027. The amendment also allows the company to include the net value of its Bitcoin derivatives positions as collateral, providing greater flexibility to manage Bitcoin price volatility. Following the update, the company has no scheduled principal payments due until June 2027.

Value
$165M
Counterparty
Kraken
Term
through Dec 2027
4:35 PM ET 10-Q
Financial Results Spero Therapeutics, Inc. SPRO

Spero Therapeutics Q3 2026 Results: Net Loss of $44.3M, Loss Widens

Spero Therapeutics reported that the FDA approved GSK’s NDA resubmission for Utebzi in June 2026, shifting the company's focus to the development of SP001. As of November 6, 2026, the company had 58,264,577 shares of common stock outstanding and continues to rely on milestone payments and royalties from its GSK partnership to fund operations.

Key figure
Net loss $44.3M
4:35 PM ET Form 4
Insider Selling Magnite, Inc. MGNI

Magnite Insider Katie Seitz Evans Sells $758K of Stock

Katie Seitz Evans sold 26,178 shares of Magnite, Inc. at $28.96 a share, worth $758K in total on Nov 9, 2026. Shares held after the trade: 415,622 (-5.9%).

Value
$758K
Shares
26,178
Price
$28.96
Holding change
-5.9%
Trade date
Nov 9, 2026
4:35 PM ET 8-K
Financial Results CapsoVision, Inc CV

CapsoVision Financial Results

CapsoVision reported Q3 2026 revenue of $3.6 million and a gross margin of 49%, while highlighting the recent FDA clearance and launch of its AI Highlights tool. The company also completed enrollment for its second-generation CapsoCam Colon study and raised approximately $19.5 million in net proceeds through a registered direct offering and ATM program during the quarter.

Term
Q3 2026

“The FDA clearance and subsequent U.S. launch of AI Highlights marks an important step forward for CapsoVision. Our four-camera, 360-degree panoramic capsule already provides physicians with a differentiated view of the small bowel. By combining that imaging capability with AI-assisted review, we believe we can reduce reading time, improve detection accuracy compared with manual review, and give physicians an additional level of diagnostic confidence.”

Johnny Wang, President and Chief Executive Officer

“At the same time, completing enrollment in our colon clinical study brings us closer to our planned FDA submission by year end, which we believe represents a substantially larger market opportunity. With the support of our existing shareholders through our recent financing, we are focused on translating these milestones into broader adoption and long-term growth.”

Johnny Wang, President and Chief Executive Officer
4:35 PM ET 8-K
Financial Results WhiteHawk Minerals Corp. WHK

WhiteHawk Minerals Financial Results

WhiteHawk Minerals Corp. reported Q3 2026 financial results including record production of 71.3 MMcfe/d and net income of $6.9 million. Concurrently, the company announced the $41.0 million acquisition of mineral and royalty interests in the Marcellus/Appalachian Basin from Three Rivers Royalty II, LLC. The company also declared a quarterly dividend of $0.50 per share.

Counterparty
Three Rivers Royalty II, LLC

“Continuing the momentum, WhiteHawk is benefiting from its base business and two-pronged acquisition strategy, driving an increase in Cash Available for Distribution and net asset value. We continue to benefit directly from our best-in-class operators’ performance and growth potential. We are particularly excited by EQT’s pending acquisition of Range, which brings together two of our largest Appalachia operators. We believe the combined company’s scale, inventory depth and low-cost structure are well aligned with WhiteHawk’s interests and further support the long-term development of our core mineral position. At the same time, our two-pronged acquisition strategy continues to deliver. Since our IPO, we have signed 22 acquisitions totaling $157.3 million, including 20 ground game transactions totaling over $11 million. We believe these transactions, and execution on our acquisition pipeline, will continue to drive meaningful value for shareholders in the short, medium and long term.”

Daniel Herz, Chairman, President and Chief Executive Officer
4:34 PM ET 8-K
Capital Raise PepGen Inc. PEPG

PepGen Capital Raise of $125M

PepGen Inc. entered into an underwriting agreement to sell 25,000,000 shares of common stock at a public offering price of $5.00 per share. The company expects to raise approximately $125.0 million in gross proceeds (excluding the underwriters' 30-day option for an additional 3.75 million shares) to fund clinical development and general corporate purposes.

Value
$125M
4:34 PM ET 10-Q
Financial Results Altimmune, Inc. ALT

Altimmune Q3 2026 Results: Net Loss of $31.6M, Loss Widens

Altimmune, Inc. reported a net loss of $77.0 million for the nine months ended September 30, 2026, compared to $60.7 million in the prior year, driven by increased research and development expenses. The company significantly strengthened its balance sheet through public and direct offerings, ending the period with $495.6 million in total assets, including $265.1 million in cash and investments.

Key figure
Net loss $31.6M
4:34 PM ET Form 4
Insider Selling Kiniksa Pharmaceuticals International, plc KNSA

Kiniksa Pharmaceuticals International CAO Michael R. Megna Sells $1.11M of Stock

Michael R. Megna, CAO, sold 11,280 shares of Kiniksa Pharmaceuticals International, plc at $98.54 a share, worth $1.11M in total on Nov 9, 2026. Shares held after the trade: 12,697 (-47.0%).

Value
$1.11M
Shares
11,280
Price
$98.54
Role
CAO
Holding change
-47.0%
Trade date
Nov 9, 2026
4:34 PM ET Form 4
Insider Buying Frp Holdings, Inc. FRPH

Frp Holdings CEO John D. Baker III Buys $99.1K of Stock

John D. Baker III, CEO, bought 5,263 shares of Frp Holdings, Inc. at $18.80 to $18.98 a share (average $18.84) in 2 transactions, worth $99.1K in total between Nov 10, 2026 and Nov 11, 2026. Shares held after the trade: 308,854 (+1.4%).

Value
$99.1K
Shares
5,263
Average price
$18.84
Role
CEO
Holding change
+1.4%
Trade date
Nov 10, 2026 to Nov 11, 2026
4:33 PM ET 6-K
Financial Results Standard Lithium Ltd. SLI

Standard Lithium Q3 2026 Results: Net Loss of $36.7M, Loss Widens

Standard Lithium Ltd. changed its functional currency from CAD to USD effective July 1, 2026, reflecting its advancing U.S. development projects. The company reported a carrying amount of $210.5 million for its equity method investment in the Smackover Lithium joint venture with Equinor as of September 30, 2026.

Key figure
Net loss $36.7M
4:33 PM ET 10-Q
Financial Results Net Power Inc. NPWR

Net Power Q3 2026 Results: Net Loss of $6.46M, Loss Narrows

Net Power Inc. is a non-accelerated filer and emerging growth company focused on power generation technology. The filing highlights significant risks including a pause in Texas data center permits, the need for additional capital, and the full impairment of its La Porte Demonstration Facility assets.

Key figure
Net loss $6.46M
4:33 PM ET 10-Q
Financial Results First Keystone Corp FKYS

First Keystone Q3 2026 Results: Net Income $3.74M, Up 33.2% YoY

First Keystone Corp reported a net income of $9.475 million for the nine months ended September 30, 2026, up from $6.775 million in the prior year period. Total assets grew significantly to $1.726 billion from $1.531 billion at year-end 2025, primarily driven by a $178 million increase in total deposits.

Key figure
Net income $3.74M · +33.2% YoY
4:33 PM ET 10-Q
Financial Results Fluent, Inc. FLNT ▶ Call

Fluent Q3 2026 Results: Net Loss of $3.12M, Loss Narrows

Fluent, Inc. reported a net loss of $3.1 million for the third quarter of 2026, an improvement from a $7.6 million loss in the prior year period, driven by a 14% increase in revenue to $53.6 million. For the nine months ended September 30, 2026, the company generated $2.8 million in cash from operating activities compared to a $4.3 million outflow in 2025. Total shareholders' equity declined significantly from $18.2 million at the end of 2025 to $5.6 million as of September 30, 2026.

Key figure
Net loss $3.12M
4:33 PM ET 8-K
M&A Deal LifeStance Health Group, Inc. LFST

LifeStance Health Group M&A Deal with Selling Stockholders

LifeStance Health Group, Inc. entered into an underwriting agreement for a secondary offering of 45,000,000 shares of common stock sold by existing stockholders. The company did not receive any proceeds from the sale, but it repurchased 2,000,000 of these shares from the underwriters as part of the transaction.

Counterparty
Selling Stockholders
4:33 PM ET Form 4
Insider Selling Magnite, Inc. MGNI

Magnite CAO Haas Sullivan Sells $71.8K of Stock

Haas Sullivan, CAO, sold 2,427 shares of Magnite, Inc. at $29.59 a share, worth $71.8K in total on Nov 11, 2026. Shares held after the trade: 95,127 (-2.5%).

Value
$71.8K
Shares
2,427
Price
$29.59
Role
CAO
Holding change
-2.5%
Trade date
Nov 11, 2026
4:32 PM ET 8-K
Investor Presentation USA Compression Partners, LP USAC

USA Compression Partners Investor Presentation

Senior management of USA Compression Partners, LP will attend a Texas Capital Securities investor event on November 17 and 18, 2026. The company will participate in meetings with the investment community and will post related presentation materials to its website prior to the event.

Counterparty
Texas Capital Securities
4:32 PM ET 8-K
Financial Results Upexi, Inc. UPXI

Upexi Financial Results

Upexi, Inc. reported fiscal first quarter 2027 results, highlighted by net income of $89.1 million, which was primarily driven by $102 million in unrealized gains on its digital asset treasury. The company significantly strengthened its balance sheet, reporting stockholders' equity of $49.2 million compared to a deficit in the prior quarter, and reduced its interest rate on BitGo borrowings from 11.5% to 7.5%.

Term
Q1 2027

“During the first quarter of fiscal 2027, we strengthened our balance sheet by increasing our Solana treasury to approximately 2.35 million SOL, increasing our cash on hand to $6.4 million, and increasing our stockholders’ equity to $49.2 million. Additionally, in September we successfully reduced the interest rate on our BitGo borrowings from 11.5% to 7.5%, a reduction we expect to lower annual interest expense by approximately $2.3 million.”

Allan Marshall, Chief Executive Officer of Upexi
4:32 PM ET 10-Q
Financial Results Avax One Technology Ltd. AVX

Avax One Technology Q3 2026 Results: Turns Profitable, Net Income $49.9M

AVAX ONE TECHNOLOGY LTD. reported a net loss of $31.6 million for the nine months ended September 30, 2026, despite a significant increase in revenue to $7.8 million compared to $1.3 million in the prior year. The company's financial position was impacted by $10.9 million in unrealized losses on digital assets and $5.3 million in interest accretion on debentures, though it achieved a net income of $49.9 million in the third quarter due to a favorable market valuation swing of $55.1 million.

Key figure
Net income $49.9M
4:32 PM ET 10-Q
Financial Results First Capital Inc FCAP

First Capital Q3 2026 Results: Net Income $5.1M, Up 14.0% YoY

First Capital, Inc. reported net income of $14.2 million for the nine months ended September 30, 2026, up from $11.5 million in the prior year period, driven by higher net interest income. Total assets remained stable at $1.27 billion, while stockholders' equity decreased slightly to $135.7 million due to a significant increase in accumulated other comprehensive loss from unrealized losses on securities.

Key figure
Net income $5.1M · +14.0% YoY
4:32 PM ET Form 4
Insider Selling Illumina, Inc. ILMN

Illumina VP, CAO Scott D. Ericksen Sells $58.1K of Stock

Scott D. Ericksen, VP, CAO, sold 267 shares of Illumina, Inc. at $217.76 a share, worth $58.1K in total on Nov 10, 2026. Shares held after the trade: 14,029 (-1.9%).

Value
$58.1K
Shares
267
Price
$217.76
Role
VP, CAO
Holding change
-1.9%
Trade date
Nov 10, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.